DMACNCMHealthcare·Biotechnology#270 in industry

DiaMedica Therapeutics Inc.

Reports in 15d· 2026-05-12

-27.9% · 90d

$6.32

-0.01 (-0.16%)

After-Hours $6.32(+0.00)

News

(1)

March 2026

Mar 31, 20263 weeks ago8-KHealthcare

DiaMedica Therapeutics Inc. — 8-K Filing

DMACDiaMedica Therapeutics Inc.

# 🧾 What This Document Is This is a **Form 8-K**, a required report companies file with the SEC to announce major news. Attached to it is **Exhibit 99.1**, which is DiaMedica's detailed press release. In simple terms, the company is using this to officially share its 2025 financial results and upda

Read summaryView on SEC EDGAR

Key Data

Market Cap$340.5M

Open$6.28

Prev Close$6.33

Day Range$6.23 – $6.48

52W Range$3.48 – $10.42

Volume96,509

P/E (TTM)—

EPS$-0.70

Dividend Yield—

Beta1.15

Price Target$15.50(+145.3%)

Next Earnings2026-05-12(15d)

Analyst Ratings

Strong Buy5 analysts

Buy 5Hold 0Sell 0

About

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Healthcare · Biotechnology

35 employees

www.diamedica.com